180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the
“Company”), a clinical-stage biotechnology company focused on the
development of novel drugs that fulfill unmet needs in inflammatory
diseases, fibrosis and pain, today announced the formation of
a scientific advisory board (SAB).
Dr. Jonathan Rothbard, 180 Life Sciences Chief Scientific
Officer stated, “We are pleased to announce the formation of the
scientific advisory board whose initial composition will
include Drs. Raphael Mechoulam (Hebrew University, Israel), Kevin
Tracey (Hofstra/Northwell, USA), Irene Tracey (Oxford University,
England), Chas Bountra (Oxford University, England) and Sallie Lamb
(Exeter University, England).
We believe this diverse, international, and talented group will
complement our scientific founders, Sir Marc Feldmann (Oxford,
England), Drs. Larry Steinman (Stanford, USA), and Jagdeep
Nanchahal (Oxford, England), along with myself (Stanford,
USA), to provide 180 Life Sciences with the collective vision
capable of stewarding the companies pipeline towards commercial
success."
Raphael Mechoulam
Dr. Mechoulam is a Professor of Chemistry at the Hebrew
University in Jerusalem. Often referred to as the “Godfather” of
modern cannabis medicine, Dr. Mechoulam most recently was awarded
Technion’s Harvey prize in Chemical Engineering and Medical
Sciences. He is the first scientist to isolate plant cannabinoids;
initially THC (tetrahydrocannabinol) then CBD (cannabidiol). He
also is the first to discover the human endocannabinoid system,
which is a complex cell-signaling system made up of receptors found
throughout our entire bodies. These receptors react to plant
cannabinoids to treat numerous pathological conditions. Since the
1990s, Dr. Mechoulam has collaborated with 180 Life Sciences
founder, Marc Feldmann, establishing the role of CBD as an
anti-inflammatory agent. As a scientific collaborator and part of
the SAB, he will provide unique guidance to the nonaddictive
cannabinoid program.
Kevin Tracey
Dr. Tracey, a neurosurgeon and inventor, is the president and
CEO of the Feinstein Institute for Medical Research, Professor of
Neurosurgery Molecular Medicine at Donald and Barbara Zucker
School of Medicine at Hofstra/Northwell, and President of the
Elmezzi Graduate School of Molecular Medicine in Manhasset, New
York. Trained as both a neurosurgeon and immunologist, he
discovered the mechanism by which neurons control the immune
system. He has pioneered the development of electroceuticals, which
use electrical stimulation of the nervous system to treat
inflammation. He is the founder of SetPoint Medical, a
company targeting a7 acetylcholine choline receptor with an
electronic device in the vagus nerve. He has taken this
approach from pre-clinical studies into early human clinical
studies to treat rheumatoid arthritis. He is a valuable member of
our team as we seek to develop an orally bioavailable small
molecule to stimulate the vagus nerve to treat inflammation.
Chas Bountra
Professor Bountra is the Head of Translational Medicine and the
Pro-Vice Chancellor for Innovation at the University of Oxford. He
brings a wealth of pharmaceutical science experience to the board,
previously being Vice President and Head of Biology at
GlaxoSmithKline. He was involved in the identification of more than
40 clinical candidates for many gastro-intestinal, inflammatory and
neuro-psychiatric diseases. Professor Bountra has worked with 180
Life Sciences and its precursor companies since their inception and
he has unparalleled links to large pharma.
Irene Tracey
Professor Tracey is a world expert in acute and chronic
pain and in the use of advanced neuroimaging to study
mechanisms related to pain, analgesia as well as
anaesthesia-induced altered states of consciousness in the human
brain. She is currently Professor of Anaesthetic Neuroscience,
Pro-Vice Chancellor and Warden (Merton College) at the University
of Oxford. She was the former Chair and Head of the Nuffield
Department of Clinical Neurosciences and Director of the Oxford
Centre for Functional Magnetic Resonance Imaging of the Brain
(FMRIB) prior to taking up her current roles. Her
many honors include the Feldberg Prize, Fellowship of Academy
of Medical Sciences (UK) and Member of Academy of Europe. Most
recently she was elected to be the next President of the
Federation of European Neuroscience societies. She serves on
the Council to the Medical Research Council in the UK. She will
provide 180 Life Sciences guidance in the preclinical and clinical
stages of the development of novel compounds for pain relief.
Sallie Lamb
Dr. Lamb is an expert in clinical trial design and medical
statistics to develop pragmatic clinical trial designs to capture
the effectiveness and cost-effectiveness of a variety of health
technologies. Currently she is the Mireille Gillings Professor of
Health Innovation, University of Exeter. Prior to moving to Exeter,
she led the Oxford Centre for Applied Health Care Research and
Leadership and was the Senior Investigator for the Royal College of
Surgeons Clinical Trials Unit and Oxford Biomedical Research Unit.
She is a NIHR Senior Investigator, and was the first female Chair
of the Health Technology Assessment Program Funding Board.
In summary, Dr. Rothbard notes, “We believe the caliber and
quantity of world class medical professionals willing to join our
newly formed scientific advisory board speaks to the quality of our
existing team, and more importantly our pipeline. With our recent
positive, statistically significant Phase 2b results in Dupuytren’s
Contracture, having met both primary and secondary endpoints with
no severe adverse events, we are working with our regulatory
partner Kinexum to meet with the US Food and Drug Administration
(FDA) and the UK equivalent, the Medicines and Healthcare products
Agency (MHRA), to map out the next steps towards ultimate
commercialization. We believe that these recent results also bode
well for our upcoming frozen shoulder trial. This positive data,
combined with the comprehensive skill sets and resources brought to
the table by our new scientific advisory board members, positions
the company well going forward.”
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical-stage biotechnology
company focused on the development of novel drugs that fulfill
unmet needs in inflammatory diseases, fibrosis and pain by
leveraging the combined expertise of luminaries in therapeutics
from Oxford University, the Hebrew University and Stanford
University. 180 Life Sciences is leading the research into solving
one of the world’s biggest drivers of disease – inflammation. The
Company is driving groundbreaking studies into clinical programs,
which are seeking to develop novel drugs addressing separate areas
of inflammation for which there are no effective therapies. The
Company’s primary platform is a novel program to treat fibrosis
using anti-TNF (tumor necrosis factor).
Forward-Looking Statements
This press release includes "forward-looking statements",
including information about management’s view of the Company’s
future expectations, plans and prospects, within the safe harbor
provisions provided under federal securities laws, including under
The Private Securities Litigation Reform Act of 1995 (the “Act”).
Words such as “expect,” “estimate,” “project,” “budget,”
“forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believes,” “predicts,” “potential,” “continue” and
similar expressions are intended to identify such forward-looking
statements. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from the expected results and, consequently, you
should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements and factors that
may cause such differences include, without limitation, the
uncertainties associated with the clinical development and
regulatory approval of 180 Life Science’s drug candidates,
including potential delays in the enrollment and completion of
clinical trials; the potential that earlier clinical trials and
studies may not be predictive of future results; 180 Life Sciences’
reliance on third parties to conduct its clinical trials, enroll
patients, and manufacture its preclinical and clinical drug
supplies; the ability to come to mutually agreeable terms with such
third parties and partners, and the terms of such agreements;
estimates of patient populations for 180 Life Sciences planned
products; unexpected adverse side effects or inadequate therapeutic
efficacy of drug candidates that could limit approval and/or
commercialization, or that could result in recalls or product
liability claims; 180 Life Sciences’ ability to fully comply with
numerous federal, state and local laws and regulatory requirements,
as well as rules and regulations outside the United States, that
apply to its product development activities; the timing of filing,
the timing of governmental review, and outcome of, planned
Investigational New Drug (IND) applications for drug candidates;
current negative operating cash flows and a need for additional
funding to finance our operating plans; the terms of any further
financing, which may be highly dilutive and may include onerous
terms; statements relating to expectations regarding future
agreements relating to the supply of materials and license and
commercialization of products; the availability and cost of
materials required for trials; the risk that initial drug results
will not be able to be replicated in clinical trials or that such
drugs selected for clinical development will not be successful;
challenges and uncertainties inherent in product research and
development, including the uncertainty of clinical success and of
obtaining regulatory approvals; uncertainty of commercial success;
the inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory
approval process; the progress of our clinical trials; our ability
to find and enter into agreements with potential partners; our
ability to attract and retain key personnel; changing market and
economic conditions; our ability to produce acceptable batches of
future products in sufficient quantities; unexpected manufacturing
defects; manufacturing difficulties and delays; competition,
including technological advances, new products and patents attained
by competitors; challenges to patents; product efficacy or safety
concerns resulting in product recalls or regulatory action; changes
in behavior and spending patterns of purchasers of health care
products and services; changes to applicable laws and regulations,
including global health care reforms; expectations with respect to
future performance, growth and anticipated acquisitions; the
continued listing of the Company on The NASDAQ Stock Market;
expectations regarding the capitalization, resources and ownership
structure of the Company; expectations with respect to future
performance, growth and anticipated acquisitions; the ability of
the Company to execute its plans to develop and market new drug
products and the timing and costs of these development programs;
estimates of the size of the markets for its potential drug
products; the outcome of current litigation involving the Company;
potential future litigation involving the Company or the validity
or enforceability of the intellectual property of the Company;
global economic conditions; geopolitical events and regulatory
changes; the expectations, development plans and anticipated
timelines for the Company's drug candidates, pipeline and programs,
including collaborations with third parties; access to additional
financing, and the potential lack of such financing; and the
Company’s ability to raise funding in the future and the terms of
such funding. These risk factors and others are included from time
to time in documents the Company files with the Securities and
Exchange Commission, including, but not limited to, its Form 10-Ks,
Form 10-Qs and Form 8-Ks. These reports and filings are available
at www.sec.gov. All subsequent written and oral forward-looking
statements concerning the Company, the results of the Company’s
clinical trial results and studies or other matters and
attributable to the Company or any person acting on its behalf are
expressly qualified in their entirety by the cautionary statements
above. Readers are cautioned not to place undue reliance upon any
forward-looking statements, which speak only as of the date made,
including the forward-looking statements included in this press
release, which are made only as of the date hereof. The Company
cannot guarantee future results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance on
these forward-looking statements. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statement to reflect
any change in its expectations or any change in events, conditions
or circumstances on which any such statement is based, except as
otherwise provided by law.
Investors:
Jason AssadDirector of IR180 Life Sciences Corp(678)
570-6791Jason@180lifesciences.com
Media Relations:
Russo PartnersDavid
SchullDavid.Schull@russopartnersllc.com (212)
845-4271
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Apr 2023 to Apr 2024